Baxter Healthcare SA

24.11.2005 – 10:15
Kiovig, Baxter's new ivig Product receives unanimous postive opinion in Europe as replacement therapy for immunodeficiencies and for immunomodulation in immune-mediated deseases
Zurich (ots) - Baxter Healthcare S.A. announced today that Baxter"s ready-to-use liquid 10% Intravenous Immunoglobulin (IVIG), has received unanimous positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). Once licensed, ...
mehr
22.09.2005 – 16:15
INTERCEPT Blood System Received TÜV Approval for Storage of Platelets up to 7 Days
Munich, Germany (ots/PRNewswire) - - Longer Storage Period Makes Platelets More Readily Available to European Transfusion Blood Centers European subsidiaries of Baxter International Inc. (NYSE: BAX) and Cerus Corporation (NASDAQ: CERS) today announced that they have received CE Mark Certification from TÜV Product Service GmbH extending the storage period ...
mehr
23.12.2004 – 12:59
Baxter Announces European Union Expanded Approval of ADVATE for use in Children With Haemophilia A Less Than Six Years Old
Zurich, Switzerland (ots/PRNewswire) - Baxter Healthcare S.A. announced today that the European Commission has granted expanded approval of ADVATE(R) (Octocog Alfa Recombinant Coagulation Factor VIII), for use in children with haemophilia A under six years of age. This expanded approval was granted on the ...
mehr